Author | City boundary He Shanshan
Edit | Lang Ming
On March 17, the joint prevention and control mechanism of the State Council held a press conference in Beijing, and held a live broadcast at the same time to introduce the latest situation of research and development of drug vaccines and testing reagents.
In the afternoon of the same day, Zhang Xinmin, director of the Biological Center of the Ministry of Science and Technology, introduced that favipiravir has completed clinical research, showing good clinical efficacy and no obvious adverse reactions. In addition, for the blockade of the transition from light and ordinary to heavy, the focus is on promoting chloroquine phosphate, favipiravir and traditional Chinese medicine. At present, favipiravir has achieved mass production, and the clinical supply is guaranteed. After expert argumentation, it has been recommended to be included in the diagnosis and treatment plan as soon as possible.
According to the data, fapiravir (also known as favilavir), which was listed in Japan in 2014, currently zhejiang Haizheng Pharmaceutical has the only approval number of the drug in China.
(Screenshot source: Haizheng Pharmaceutical Drug Registration Approval and Drug Clinical Trial Approval Announcement)
On February 15, 10 days after the Drug Review Center (CDE) of the State Food and Drug Administration accepted the application, it approved its conditional listing for the treatment of influenza indications, becoming the fastest product in history to complete the application and be approved for listing.
It is worth noting that the drug registration approval issued by Haizheng Pharmaceutical on February 17 shows that the indications for this drug are for the treatment of novel or recurrent influenza in adults (limited to when other anti-influenza virus drugs are ineffective or ineffective). The indications approved for favipiravir at that time were only anti-influenza drugs, not for the treatment of covid-19 pneumonia.
The conclusion of the trial approval shows that according to the "Drug Administration Law", "Drug Registration Management Measures" and "Drug Special Approval Procedures", after the review and approval of the special expert group, the product was approved for clinical trials in an emergency. Indications are novel coronavirus pneumonia.
After 1 month, the drug finally completed clinical studies.
The city noted that on February 19, the hanging network information released by the Shandong Provincial Drug Procurement Platform showed that the price of 40 tablets / box of 0.2g specifications was 780 yuan, and the price of 20 tablets was 398 yuan. It means that the price of a single tablet of this medicine is about 20 yuan / tablet.
Wind shows that Haizheng Pharmaceutical was founded in 1956 and listed in 2000, belongs to the industry of Western medicine, and the current total market value is 12.5 billion yuan.